ArticleFrontiers in physiology2024
Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Article in Frontiers in physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.World journal of gastroenterology · 2026Review
- Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease.Frontiers in cellular and infection microbiology · 2026Article
- Microbial exposure and host responses to infection reshape the disease trajectory of MASLD.Frontiers in cellular and infection microbiology · 2026Review
- Hepatitis B virus, alcohol, and liver cancer.Frontiers in oncology · 2026Review
- Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact.Journal of health, population, and nutrition · 2025Article
- When Metabolic Dysfunction-Associated Steatotic Liver Disease Meets Viral Hepatitis.Journal of clinical medicine · 2025Review
- A comprehensive analysis of percutaneous liver biopsy characteristics and pathological manifestations in a large patient cohort (2009-2024).BMC gastroenterology · 2025Article
- Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B.Clinical and molecular hepatology · 2025Review
- Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction.World journal of hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.